arrow
C

Charles E. Canter

St. Louis Children's Hospital
H指数:68
被引数:3.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rationale and design of CHD PULSE: Congenital Heart Disease Project to Understand Lifelong Survivor Experience

CHD脉冲的原理和设计: 了解终身幸存者经验的先天性心脏病项目

2024-12-011
PRE
Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial

沙库巴曲/缬沙坦治疗小儿心力衰竭 (panorame-hf): 一项随机、多中心、双盲试验

2024-11-260
PRE
Outstanding Research Award in Pediatric Cardiology: Cardiomyopathy-Associated Pathogenic Variants in Pediatric Myocarditis: A Study from the Pediatric Cardiomyopathy Registry

儿科心脏病学杰出研究奖:心肌病相关致病性变异在儿童心肌炎中的研究——儿科心肌病登记研究

2024-11-120
PRE
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial
2024-08-010
PRE
Progressive Left Ventricular Remodeling for Predicting Mortality in Children With Dilated Cardiomyopathy: The Pediatric Cardiomyopathy Registry
2024-01-161
OAAI
Impact of donor-specific anti-HLA antibody on cardiac hemodynamics and graft function 3 years after pediatric heart transplantation: First results from the CTOTC-09 multi-institutional study
2023-12-010
PRE
Quality of Life in EarlyStage Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial
2023-11-070
PRE
Cardiac Remodeling in Subclinical Hypertrophic CardiomyopathyThe VANISH Randomized Clinical Trial
2023-11-019
OA
Cardiac imaging and biomarkers for assessing myocardial fibrosis in children with hypertrophic cardiomyopathy
2023-10-013
OAAI
Transforming Growth Factor-β Analysis of the VANISH Trial Cohort
2023-04-011
OA
The genetic architecture of pediatric cardiomyopathy
2022-02-0134
OAAI
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial

缬沙坦治疗早期肥厚型心肌病: 一项2期随机试验

2021-09-2379
OA
Genetic Causes of Cardiomyopathy in Children: First Results From the Pediatric Cardiomyopathy Genes Study
2021-05-0437
OAAI
Baseline Characteristics of the VANISH Cohort
2019-12-0111
OAAI